

Supporting Information

Murata et al. 10.1073/pnas.1110011108




Fig. S1. (A–C) Host hematopoietic prostaglandin D₂ (PGD₂) synthase (H-PGDS) deficiency accelerates tumor growth and angiogenesis in B16 melanoma. Melanoma cells (1×10^6) were injected subcutaneously on the backs of mice, and tumor growth was monitored (A, $n = 8$ each). Tumor sections (day 14) were labeled with anti-PECAM-1 (platelet endothelial cell adhesion molecule) antibody (B) and the labeled area was quantified relative to total pixel density (C, $n = 8$ each). (Scale bar in B, 50 μm .) (D–I) Absence of bone marrow-derived PGD₂ decreases necrotic/apoptotic cell death, and increases angiogenesis in growing Lewis lung carcinoma (LLC) tumor. Cytoplasmic proteins extracted from tumor mass (day 14) were applied for Western blot to detect the high mobility group box 1 (HMGB-1) protein leakage from nuclei. Total protein extracts were applied to detect cleaved caspase-3 or an endothelial marker, VEGFR-2. Band intensities were normalized and shown as the ratio of β -actin ($n = 5$ each). Anti-HMGB-1, cleaved caspase-3 (Cell Signaling), VEGFR-2 (R&D Systems), and β -actin (Sigma-Aldrich) antibodies were used. (J and K) Host H-PGDS deficiency decreases pericyte-coverage in the tumor-neovasculature. Tumor sections were labeled with antidesmin antibody (Abcam) and anti-PECAM-1 antibody (J) (Scale bar, 50 μm). The pixel density of desmin was normalized to total PECAM-1⁺ pixel density (K, $n = 5$ each). Results are expressed as means \pm SEM. * $P < 0.05$ compared with WT or H-PGDS^{-/-}, respectively.




Fig. 54. (A and B) Mast cell reconstitution in back skin and lung on Kit^{W-sh/W-sh} mice. BMMCs were transferred by intradermal and by tail-vein injection into Kit^{W-sh/W-sh} mice. Eight weeks after the injection, tissues were dissected and subjected to Toluidine blue staining. The number of metachromatically stained cells were normalized to field area (A and B, results are expressed as means \pm SEM, $n = 4$; * $P < 0.05$ compared with WT^{BMMC}-reconstituted Kit^{W-sh/W-sh} mice or H-PGDS^{-/-}BMMC-reconstituted mice, respectively). (C) Mast cell reconstitution in tumor on Kit^{W-sh/W-sh} mice. BMMCs were transferred into Kit^{W-sh/W-sh} mice as mentioned above. Additionally, after LLC transplantation, BMMCs were injected by tail vein every 5 d. Fourteen days after the LLC transplantation, tumors were excised, and processed for Toluidine blue staining (Scale bar, 50 μ m). (D) H-PGDS deficiency accelerates and D prostanoid agonism or PGJ₂ attenuates TNF- α production of BMMC. BW245C (100 nM), DK-PGD₂ (100 nM), 15d-PGJ₂ (15-deoxy-^{12,14}-PGJ₂; 30 nM), or Troglitazone (300 nM) was treated 10 min before the LPS-stimulation. Twenty-four hours after stimulation with 10 ng/mL LPS, supernatants of BMMC culture were collected and applied to ELISA. Results are expressed as means \pm SEM, $n = 4-8$, * $P < 0.05$ compared with WT or H-PGDS^{-/-}, respectively.

